Setting the Standard in Gene Therapy, Together
Gene therapies have potential to transform the way we treat conditions like hereditary genetic disorders, cancer, and infectious diseases, and have become one of the most rapidly evolving fields in regenerative medicine. Delivering them requires optimizing processes upstream and downstream to retain critical quality attributes.
To meet the growing demand for viral vectors in clinical therapeutics, scientists need solutions that offer reproducible performance and scalability with a simplified path to regulatory approvals.
Scale From Screening to Commercial with Sartobind®
Sartorius membrane chromatography solutions transform purification into highly productive processes, from drug discovery to commercial production:
- Our scalable chromatography portfolio can be tailored to meet diverse process needs, enabling high utilization of chromatographic material, especially in applications where resin materials tend to be underutilized, such as clinical batches or single-use applications.
- Convective membrane pores support high flow rates, with recommended residence times of 12–20 seconds for capture applications and up to 3 seconds for flow-through applications.
- Ready-to-use formats eliminate the need for column packing hardware and costly cleaning validation.
Related Assets
Robust and Scalable Membrane Chromatography for Adeno-Associated Virus Capture Using Sartobind S
PDF | 820.6 KB
Start with a Sample or Speak with an Expert.
References & Notes
1. Haslam, A. et al. (2024) ‘Estimation of eligibility for and response to CAR T therapy in the US’, Blood Advances, 8(4), pp. 1032–1036.
2. Mikhael, J., Fowler, J. and Shah, N. (2022) ‘Chimeric antigen receptor T cell therapies: Barriers and solutions to access’, JCO Oncology Practice, 18(11), pp. e1641–e1650.